FOUNDATIONONE®CDx

PATIENT
Chu, Chih-Peng

TUMOR TYPE
Brain glioma (NOS)
COUNTRY CODE
TW

REPORT DATE
28 Jul 2022
ORDERED TEST #
ORD-1416204-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Brain glioma (NOS)
NAME Chu, Chih-Peng
DATE OF BIRTH 28 January 1963
SEX Male
MEDICAL RECORD # 21667243

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Brain
SPECIMEN ID S111-23410 E (PF22083)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 21 June 2022
SPECIMEN RECEIVED 20 July 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 4 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KIT amplification
PDGFRA V536E - subclonal, amplification†
CDK6 amplification
MTAP loss
MYC amplification
CDKN2A/B CDKN2B loss, CDKN2A loss
KDR amplification

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with potential clinical benefit **approved in another tumor type**: **Imatinib** (p. 9), **Nilotinib** (p. 9), **Sorafenib** (p. 10), **Sunitinib** (p. 10)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 11)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section
Tumor Mutational Burden - 4 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
KIT **-** amplification	none	Imatinib
		Nilotinib
		Sorafenib
10 Trials *see p. 13*		Sunitinib
PDGFRA **-** V536E - subclonal, amplification	none	Imatinib
6 Trials *see p. 17*		Sorafenib
CDK6 **-** amplification	none	none
10 Trials *see p. 11*		
MTAP **-** loss	none	none
1 Trial *see p. 15*		
MYC **-** amplification	none	none
4 Trials *see p. 16*		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - CDKN2B loss, CDKN2A loss ..... p. 7

KDR - amplification ..... p. 8

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI-High has been reported in 3-8% of adult or pediatric astrocytomas and was generally not associated with Lynch syndrome[6-8]. Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[9-11]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[9], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[12]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[9], in GBMs with a previous lower grade astrocytoma[10], and in giant cell GBM compared to classic GBM[11].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[13]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[13-15]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[16-18]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[13,15,17-18].

BIOMARKER

Tumor Mutational Burden

RESULT
4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[19-21], anti-PD-1 therapies[19-22], and combination nivolumab and ipilimumab[23-28]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[19,29-30]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[31-32] or anti-PD-L1[33] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)[34]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[35-36]. Increased TMB has been reported to correlate with higher tumor grade in glioma[37] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[31], as well as with shorter OS of patients with diffuse glioma[38].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[39-40] and cigarette smoke in lung cancer[41-42], treatment with temozolomide-based chemotherapy in glioma[43-44], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[45-49], and microsatellite instability (MSI)[45,48-49]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[19,29-33].

GENE
KIT

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, primarily in gastrointestinal stromal tumor (GIST), melanoma, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to TKIs including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, apatinib, avapritinib, and ripretinib[50-58]. The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT-mutated, imatinib-resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus[59]. However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation[60]. The role of KIT amplification as a biomarker for response to mTOR inhibitors has not been investigated (PubMed, Mar 2022). Clinical benefit has been observed for patients with KIT amplified or overexpressing tumors following treatment with imatinib[61-71], nilotinib[72], sorafenib[73-76], and sunitinib[77-78], suggesting that KIT amplification may be sensitive to these inhibitors. However, evidence demonstrating clinical benefit for regorafenib, dasatinib, pazopanib, or ponatinib in the context of KIT amplified or overexpressing tumors is limited. One patient with KIT/PDGFRA/KDR-amplified GBM experienced a PR on ripretinib[79-80] .

FREQUENCY & PROGNOSIS

In the TCGA datasets, KIT amplification has been reported in 2.5% of lower grade gliomas (grades 2 and 3)[81] and 9.2% of glioblastomas (Grade 4 astrocytoma)[82]. KIT amplification has been variously reported in 4-47% of glioblastomas in the scientific literature[83-85]. Amplification of KIT has been strongly correlated with the presence of KDR and/or PDGFRA amplification in glioblastoma[84,86-87]. One study found no correlation between KIT amplification and overall survival in patients with glioblastoma, while a separate study reported that overexpression of KIT was associated with tumor grade and shorter survival in patients with malignant glioma[83,88].

FINDING SUMMARY

KIT (also called c-KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI_3K-AKT and RAS-MAPK signaling pathways[89]. KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein[90]. KIT has been reported to be amplified in cancer[91] and may be biologically relevant in this context[92-93].

GENE
PDGFRA

ALTERATION
V536E - subclonal, amplification

TRANSCRIPT ID
NM_006206

CODING SEQUENCE EFFECT
1607T>A

VARIANT ALLELE FREQUENCY (% VAF)
5.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib[94-131]. Sorafenib has shown clinical and preclinical activity against the FIP1L1-PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)[132-137]. Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1-PDGFRA or activating mutations[110,138-139]; preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST[140-141]. Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib[142] or regorafenib[143-144]. Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1-PDGFRA fusion to dasatinib[134,140]. PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical[50] and preclinical[50] studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient[80]. One patient with KIT/PDGFRA/KDR-amplified GBM experienced a PR on ripretinib[79-80] .

FREQUENCY & PROGNOSIS

PDGFRA amplification has been suggested to be more common in higher grade astrocytomas than in lower grade astrocytomas; studies have reported PDGFRA amplification in 16.3% (27/166) of Grade 2 astrocytomas and in 23.6% (91/386) of Grade 3 and 4 astrocytomas analyzed[86,145-146]. PDGFRA amplification has been reported in 5.2-33% of glioblastoma cases[82-84,145,147-148]. PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)[149]. PDGFRA mutations have been reported in 0-5% of lower grade glioma and glioblastoma samples[82,150-156], Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio-Johnson et al., 2014; 24336570, cBio-Thomas et al., 2017; 28472509, cBio-Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co-expression of these genes was an indicator of poor prognosis in a GBM patient cohort[157]. Amplification of PDGFRA has been associated with tumor grade and poor progression-free and overall survival in patients with glioblastoma[145,147-148]. In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis[145]. Amplification of PDGFRA has also been strongly correlated with the presence of KDR and/or KIT amplification in glioblastomas, as well as with EGFR amplification[84,86-87,158].

FINDING SUMMARY

PDGFRA encodes platelet-derived growth factor receptor alpha (PDGFR-alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK[159]. PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies[90]. Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression[85,160-162] and poor prognosis[85,145,163-164] in some subtypes of glioma. Many PDGFRA missense mutations, such as seen here, have been characterized as activating[162,165-168]. As a class, these mutations have also been shown in preclinical assays to confer sensitivity to targeted therapies, such as imatinib and crenolanib[165,167-170].

GENE
CDK6

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Tumors with CDK6 activation may be sensitive to CDK4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib[171-174]. Clinical benefit has been reported for patients with CDK6-amplified or mutated solid tumors in response to treatment with ribociclib[175-176] .

FREQUENCY & PROGNOSIS

In the Glioblastoma Multiforme (GBM) TCGA dataset, CDK6 mutation has not been found, while putative CDK6 amplification has been reported in 3% of cases[82,150]. CDK6 amplification has also been reported in GBM in the scientific literature[177-179]. Studies have reported higher expression of CDK6 in high-grade gliomas than in low-grade gliomas[180-182]. Elevated CDK6 expression in glioblastoma tumor margins was associated with reduced survival[183]. Knockdown or inhibition of CDK6 was associated with reduced proliferation of GBM cells and reduced growth of GBM xenografts[183-184].

FINDING SUMMARY

CDK6 encodes cyclin-dependent kinase 6, which regulates the cell cycle, differentiation, senescence, and apoptosis[185-187]. CDK6 and its functional homolog CDK4 are activated by D-type cyclins and promote cell cycle progression by inactivating the tumor suppressor Rb[188-189]. Amplification of the chromosomal region that includes CDK6 has been reported in multiple cancer types, and has been associated with overexpression of CDK6 protein[190-191].

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
MTAP

ALTERATION
loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A[192-193] or PRMT5 inhibition[193-195]. A Phase 1 trial of MAT2A inhibitor AG-270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss[196]. Preclinical data suggest that MTAP loss sensitizes cells to S-adenosyl-L-methionine (SAM)-competitive PRMT5 inhibitors[197], dual PRMT1 and PRMT5 inhibitors[198-200], and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S-methyl-5'-thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193[201]. In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA[202-212]. A Phase 2 study of L-alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP-deficient cancers reported no responses and SD for 24% (13/55) of patients[213]. Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed[214].

FREQUENCY & PROGNOSIS

MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers[215-216]; such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma[217], gastrointestinal stromal tumors[218], mantle cell lymphoma (MCL)[219], melanoma[220-221], gastric cancer[222], myxofibrosarcoma[223], nasopharyngeal carcinoma[224], ovarian carcinoma[215] and non-small cell lung cancer[225]. MTAP loss was not prognostic in pediatric B-cell acute lymphocytic leukemia[226] or in astrocytoma[227]. However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples[228], and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM[229]. Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma[230-231], esophageal cancer[232-233], osteosarcoma[234], and CRC[235].

FINDING SUMMARY

MTAP encodes S-methyl-5'-thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity[236-237]. Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment[217,238-239], thereby reducing intracellular arginine methylation[193-195] and altering cell signaling[239-240]. MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co-deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized.

GENE
MYC

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data indicate MYC overexpression may predict sensitivity to investigational agents targeting CDK1[241-242], CDK2[243], Aurora kinase A[244-251], Aurora kinase B[252-255], glutaminase[256-259], or BET bromodomain-containing proteins[260-263], as well as agents targeting both HDAC and PI3K[264-266]. Exploratory biomarker analysis in a Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second-line therapy for patients with MYC-overexpressed small cell lung cancer but not for patients without MYC overexpression[267]. A PR was reported for a patient with MYC-amplified invasive ductal breast carcinoma treated with an unspecified Aurora kinase inhibitor and taxol[268].

— Nontargeted Approaches —

MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies[269-270]. Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5-fluorouracil and paclitaxel[271-272].

FREQUENCY & PROGNOSIS

In the TCGA dataset, MYC amplification was observed in 7% and 1.6% of lower grade glioma and glioblastoma (GBM) cases, respectively[43,82], whereas MYC mutation has been reported in <1% of GBM samples[82]. Studies have reported a small number of cases of MYC amplification in anaplastic astrocytoma[273], with one study also reporting elevated c-MYC expression in nucleus and cytoplasm, suggesting a role in tumorigenesis[274]. The effect of MYC on prognosis in glioblastoma is unclear; MYC has been reported to increase sensitivity to radiotherapy and temozolomide in some studies, while other studies have associated MYC expression with increased proliferation, tumor grade, and poor prognosis[275-277]. MYC overexpression in astrocytes resulted in increased cell growth and development of characteristics resembling GBM[278].

FINDING SUMMARY

MYC (c-MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers[279]. MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types[280]. MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes[279,281-282].

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
CDKN2A/B

ALTERATION
CDKN2B loss, CDKN2A loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib[283] and palbociclib treatment[284-285]. However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[172,175-176,286-289]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[290-291], the clinical relevance of p14ARF as a predictive biomarker is not clear. Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[292-295]. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib[171-172,175,287,296-297].

FREQUENCY & PROGNOSIS

Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas[298] and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)[82] than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)[91,299]. In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM)[147,162,300]. Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples[301]. Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression[147,302]. In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas[303-304].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[305-306]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[307-308]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[309-310]. One or more alterations observed here are predicted to result in p16INK4a loss of function[311-332]. One or more alterations seen here are predicted to result in p14ARF loss of function[315,332-335]. CDKN2B alterations such as seen here are predicted to inactivate p15INK4b[336].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[337]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[338-339]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[340-342]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[343-345]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

GENE
KDR

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical benefit for patients with ccRCC[346-350] and a patient with breast angiosarcoma[351], high VEGFR-2 expression has been associated with sensitivity to sunitinib. However, because data supporting concordance between VEGFR-2 expression and KDR genomic biomarkers are limited, it is unclear whether these therapeutic strategies would be beneficial in this case. On the basis of extensive clinical evidence across multiple tumor types, expression of plasma or tumor VEGFR-1 or VEGFR-2 has not been established as a reliable biomarker to predict response to the VEGFA-targeted agent bevacizumab[352-371]. One patient with KIT/PDGFRA/KDR-amplified GBM experienced a PR on ripretinib[79-80] .

FREQUENCY & PROGNOSIS

KDR mutation has been reported in 2.0% of glioma samples analyzed in COSMIC (Jan 2022)[149]. In the TCGA datasets, KDR amplification has been reported in 2.5% of lower grade gliomas and 6.2% of glioblastomas (grade IV astrocytoma)[81-82]. In the scientific literature, KDR amplification has been reported in 3-39% of glioblastomas analyzed[83-84]. Amplification of KDR has been strongly correlated with the presence of KIT and/or PDGFRA amplification in glioblastomas[84,86-87]. The activity of VEGFR2 has been shown to be correlated with disease progression in gliomas; a study reported constitutive activity of VEGFR2 in 71% and 15% of glioblastomas and anaplastic gliomas, respectively, but not in low grade gliomas[372-373]. In addition, increased VEGFR2 expression has been associated with poor progression-free survival in recurrent high-grade gliomas[374].

FINDING SUMMARY

KDR encodes vascular endothelial growth factor receptor 2 (VEGFR2), a member of the vascular endothelial growth factor receptor (VEGFR) family. It is a receptor tyrosine kinase that transmits signals from VEGFA and is involved in both tumor angiogenesis and vasculogenesis during development[375]. KDR amplification has been reported in many tumor types and may be oncogenic[375].

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Imatinib

Assay findings association

KIT
amplification

PDGFRA
V536E - subclonal, amplification

AREAS OF THERAPEUTIC USE

Imatinib targets the BCR-ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT-positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/ myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated[62-63,106,376] , KIT-amplified[61-64] , or KIT-expressing tumors[66-71,377-378] , KIT activating alterations may confer sensitivity to imatinib. On the basis of strong clinical evidence, PDGFRA activating mutations[96,101-102,106,131] , fusions[95,99,105,107,115,118,120,124,127,379] , and expression[104] may predict sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib[104].

SUPPORTING DATA

In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively[380]. However, other Phase 2 clinical trials of imatinib have reported no anti-tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4%[71,381] . In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low-grade glioma, but had negligible antitumor activity[382].

Nilotinib

Assay findings association

KIT
amplification

AREAS OF THERAPEUTIC USE

Nilotinib targets tyrosine kinases such as ABL (including BCR-ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine-kinase inhibitor therapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated[72,383-386] , KIT-amplified[72], or KIT-expressing tumors[387], KIT activating alterations may confer sensitivity to nilotinib.

SUPPORTING DATA

Clinical data on the efficacy of nilotinib for the treatment of CNS tumors are limited (PubMed, Jul 2022). Nilotinib has been primarily investigated as a therapeutic option for the treatment of CML or gastrointestinal stromal tumors (GIST). In the context of CML, a Phase 3 clinical trial of Ph+ patients treated with imatinib or nilotinib (300 mg or 400 mg) reported progression-free survival (PFS) rates of 93% and 97-98% and overall survival (OS) rates of 93% and 94-97%, respectively, at 4 years[388]. For imatinib-resistant Japanese patients with CML, a Phase 2 trial reported a 47.8% major medical response rate to treatment with nilotinib at 12 months[389]. A Phase 3 clinical trial of single-agent nilotinib in 240 patients with advanced GIST who failed prior treatment with imatinib or sunitinib reported no significant difference in progression-free survival between nilotinib and the best supportive care, but did report increased overall survival for nilotinib-treated patients[390]. A Phase 2 trial has shown that nilotinib was well tolerated and suggested it may be particularly useful for treating patients with GIST harboring mutations in KIT exon 17[391]. Preclinical, cell-based assays have reported efficacy for nilotinib alone and in combination with additional therapies in the context of leiomyosarcoma and synovial sarcoma[392].

Sorafenib

Assay findings association

KIT
amplification

PDGFRA
V536E - subclonal, amplification

AREAS OF THERAPEUTIC USE

Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated[393-400] or KIT-expressing tumors[73-76] , KIT activating alterations may predict sensitivity to sorafenib. On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib[136,401].

SUPPORTING DATA

Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM)[402]. A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression-free survival[403]. A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib[404]. In a Phase 1 trial in patients with high-grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone[405]. In a clinical study of sorafenib in pediatric patients with low-grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates[406].

Sunitinib

Assay findings association

KIT
amplification

AREAS OF THERAPEUTIC USE

Sunitinib is a small-molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF-1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical and preclinical data in KIT-mutated[77,407-411] or KIT-expressing tumors[77-78] , KIT activating alterations may predict sensitivity to sunitinib.

SUPPORTING DATA

Phase 2 clinical trials of sunitinib in glioblastoma have reported no significant improvement in clinical outcome[412-413] . A Phase 2 trial that examined sunitinib treatment followed by radiation therapy in patients with glioblastoma reported a median progression-free survival (PFS) of 7.7 weeks, and a median overall survival (OS) of 12.8 weeks; 83.3% (10/12) of patients experienced neurological deterioration prior to radiation therapy[414]. Another Phase 2 study that examined daily sunitinib treatment in patients with glioblastoma reported no objective response in any of the 40 patients, with a median PFS of 2.2 months and a median OS of 9.2 months; five patients in the study had stable disease for more than six months[415].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
CDK6

RATIONALE
Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.

ALTERATION
amplification

NCT04282031

PHASE 1/2

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

TARGETS
CDK4, CDK6, ER, Aromatase

LOCATIONS: Shanghai (China)

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04391595

PHASE NULL

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

TARGETS
CDK4, CDK6, ERK1, ERK2

LOCATIONS: Arizona

NCT02933736

PHASE NULL

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

TARGETS
CDK4, CDK6

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT05159245

PHASE 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

TARGETS
BRAF, KIT, RET, VEGFRs, ERBB2, ALK, ROS1, TRKA, TRKB, TRKC, SMO, PD-L1, MEK, CDK4, CDK6

LOCATIONS: Kuopio (Finland), Helsinki (Finland), Tampere (Finland)

NCT03994796

PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Washington, Oregon, Idaho, Montana

NCT05252416

PHASE 1/2

(VELA) Study of BLU-222 in Advanced Solid Tumors

TARGETS
CDK4, CDK6, ER, CDK2

LOCATIONS: Massachusetts, Texas, Florida

NCT03158389

PHASE 1/2

NCT Neuro Master Match - N^2M^2 (NOA-20)

TARGETS
ALK, RET, CDK4, CDK6, mTOR, MDM2, PD-L1, SMO

LOCATIONS: Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)

NCT04116541

PHASE 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/ Characteristics in Advanced / Metastatic Tumors.

TARGETS
CDK4, CDK6, MDM2, MET, RET, ROS1, VEGFRs

LOCATIONS: Nice (France), Lyon (France), Marseille (France), Toulouse (France), Bordeaux (France)

GENE
KIT

ALTERATION
amplification

RATIONALE
KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K-AKT-mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation. KIT/PDGFRA/KDR amplification in GBM may predict sensitivity to ripretinib.

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK

LOCATIONS: Guangzhou (China)

NCT04977453

PHASE 1/2

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

TARGETS
FGFRs, KIT, PDGFRA, RET, VEGFRs, PD-1, CTLA-4

LOCATIONS: Daejeon (Korea, Republic of), Suwon-si (Korea, Republic of), Seoul (Korea, Republic of)

NCT03564691

PHASE 1

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

TARGETS
ITL4, FGFRs, KIT, PDGFRA, RET, VEGFRs, PD-1

LOCATIONS: Seoul (Korea, Republic of), Liverpool (Australia), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington

NCT04008797

PHASE 1

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

TARGETS
Beta-catenin, CBP, FGFRs, KIT, PDGFRA, RET, VEGFRs

LOCATIONS: Osakasayama (Japan), Chuo-Ku (Japan), Chiba (Japan), Kashiwa (Japan)

NCT03025893

PHASE 2/3

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

TARGETS
CSF1R, FLT3, KIT, RET, VEGFRs

LOCATIONS: Groningen (Netherlands), Nijmegen (Netherlands), Amsterdam (Netherlands)

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT04729348

PHASE 2

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

TARGETS
FGFRs, KIT, PD-1, PDGFRA, RET, VEGFRs

LOCATIONS: Massachusetts

NCT03711058

PHASE 1/2

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

TARGETS
PD-1, PI3K

LOCATIONS: Maryland

NCT02379416

PHASE 1

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

TARGETS
ABL, KIT

LOCATIONS: Maryland

NCT04975958

PHASE 1

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

TARGETS
PI3K, PD-L1, EP4

LOCATIONS: Colorado, Oklahoma, New Jersey, Florida

GENE
MTAP

ALTERATION
loss

RATIONALE
MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.

NCT05245500	**PHASE 1/2**
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	**TARGETS** PRMT5-MTA

LOCATIONS: New York, Tennessee, Texas

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
MYC

ALTERATION
amplification

RATIONALE
MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC-dependent transcriptional programs.

NCT04983810

PHASE 1/2

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

TARGETS
CDK2, CDK9

LOCATIONS: Seoul (Korea, Republic of), Barcelona (Spain), California, Texas

NCT04742959

PHASE 1/2

Crossover Relative Bioavailability and Dose Escalation Study of TT-00420 Tablet in Patients With Advanced Solid Tumors

TARGETS
Aurora kinase A, Aurora kinase B

LOCATIONS: California, Illinois, Ohio, Texas, New Jersey

NCT04555837

PHASE 1/2

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

TARGETS
Aurora kinase A, PD-1

LOCATIONS: Texas

NCT01434316

PHASE 1

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

TARGETS
PARP, CDK1, CDK2, CDK5, CDK9

LOCATIONS: Massachusetts

GENE
PDGFRA

ALTERATION
V536E - subclonal, amplification

RATIONALE
PDGFRA amplification may predict sensitivity to imatinib and to anti-PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA-targeted therapies. KIT/PDGFRA/KDR amplification in GBM may predict sensitivity to ripretinib.

NCT03970447

PHASE 2/3

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

TARGETS
BRAF, KIT, RET, VEGFRs

LOCATIONS: Zürich (Switzerland), Basel (Switzerland), Bron (France), Utah, Michigan, New York

NCT05159245

PHASE 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

TARGETS
BRAF, KIT, RET, VEGFRs, ERBB2, ALK, ROS1, TRKA, TRKB, TRKC, SMO, PD-L1, MEK, CDK4, CDK6

LOCATIONS: Kuopio (Finland), Helsinki (Finland), Tampere (Finland)

NCT03025893

PHASE 2/3

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

TARGETS
CSF1R, FLT3, KIT, RET, VEGFRs

LOCATIONS: Groningen (Netherlands), Nijmegen (Netherlands), Amsterdam (Netherlands)

NCT04771520

PHASE 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

TARGETS
KIT, PDGFRA

LOCATIONS: Texas

NCT02379416

PHASE 1

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

TARGETS
ABL, KIT

LOCATIONS: Maryland

NCT01738139

PHASE 1

Ipilimumab and Imatinib Mesylate in Advanced Cancer

TARGETS
ABL, KIT, CTLA-4

LOCATIONS: Texas

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

BRCA2
N72S

EZH2
amplification

JAK3
R920H

MSH6
K1358fs*2

MYCN
A184S

PDGFRB
R355H

RAD51C
V351I

RPTOR
A619E

SPEN
S2292L

TSC1
N997I

XRCC2
amplification

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B or WTX)*	
APC	*AR*	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*
AURKA	*AURKB*	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*
BCL6	*BCOR*	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*
BTG2	*BTK*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK12	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*	*CDKN2C*
CEBPA	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*	*CTCF*
CTNNA1	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*	*DDR2*
DIS3	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EMSY (C11orf30)*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FANCA	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*
FGF19	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*
FH	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*
GATA6	*GID4 (C17orf39)*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3-3A (H3F3A)*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11 (MRE11A)*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD2 (WHSC1 or MMSET)*		*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*
P2RY8	*PALB2*	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*
PDGFRA	*PDGFRB*	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*
PMS2	*POLD1*	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*
PRKN (PARK2)	*PTCH1*	*PTEN*	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*
RAD51B	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*
REL	*RET*	*RICTOR*	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*
SNCAIP	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*
STK11	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C (FAM46C)*	*TET2*	*TGFBR2*	*TIPARP*
TNFAIP3	*TNFRSF14*	*TP53*	*TSC1*	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*
WT1	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*				

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV1*
ETV4	*ETV5*	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*
KMT2A (MLL)	*MSH2*	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*
RAF1	*RARA*	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***
TMPRSS2								

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT

CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version 7.0.0

The median exon coverage for this sample is 810x

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Alonso M, et al. Cancer Res. (2001) pmid: 11280776
7. Rodríguez-Hernández I, et al. PLoS ONE (2013) pmid: 24073290
8. Vladimirova V, et al. Neuropathol. Appl. Neurobiol. (2008) pmid: 18053027
9. Martinez R, et al. Oncology (2004) pmid: 15331927
10. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
11. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
12. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
13. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
14. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
15. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
16. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
17. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
18. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
19. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
20. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
21. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
22. Cristescu R, et al. Science (2018) pmid: 30309915
23. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
24. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
25. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
26. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
27. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
28. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
29. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
30. Touat M, et al. Nature (2020) pmid: 32322066
31. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
32. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
33. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
34. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
35. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
36. Johnson A, et al. Oncologist (2017) pmid: 28912153
37. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
38. Wang L, et al. BMC Cancer (2020) pmid: 32164609
39. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
40. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
41. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
42. Rizvi NA, et al. Science (2015) pmid: 25765070
43. Johnson BE, et al. Science (2014) pmid: 24336570
44. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
45. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
46. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
47. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
48. Nature (2012) pmid: 22810696
49. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
50. Evans EK, et al. Sci Transl Med (2017) pmid: 29093181
51. Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065
52. Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456
53. Demetri GD, et al. Lancet (2013) pmid: 23177515
54. Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533
55. Jawhar M, et al. Blood (2017) pmid: 28424161
56. Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773
57. Gotlib J, et al. Blood (2005) pmid: 15972446
58. Luo C, et al. Onco Targets Ther (2017) pmid: 29066909
59. Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580
60. Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218
61. Wei X, et al. Oncol. Res. (2019) pmid: 30075827
62. Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962
63. Carvajal RD, et al. JAMA (2011) pmid: 21642685
64. Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468
65. Debiec-Rychter M, et al. Gastroenterology (2005) pmid: 15685537
66. Dematteo RP, et al. Lancet (2009) pmid: 19303137
67. Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502
68. Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505
69. Alcedo JC, et al. Head Neck (2004) pmid: 15350030
70. Brandwein JM, et al. Leukemia (2011) pmid: 21403650
71. Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263
72. Lee SJ, et al. Oncologist (2015) pmid: 26424760
73. Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331
74. Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498
75. Seino S, et al. Gastroenterology (2014) pmid: 25450081
76. Li XF, et al. Med. Oncol. (2009) pmid: 18846437
77. Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812
78. Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504
79. de Groot at el., 2017; SNO Abstract ACTR-02
80. Jaku et al., 2017; ASCO Abstract 2515
81. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
82. Brennan CW, et al. Cell (2013) pmid: 24120142
83. Nobusawa S, et al. Neuropathology (2011) pmid: 21382095
84. Joensuu H, et al. J. Pathol. (2005) pmid: 16021678
85. Burford A, et al. PLoS ONE (2013) pmid: 23990986
86. Holtkamp N, et al. Neuro-oncology (2007) pmid: 17504929
87. Puputti M, et al. Mol. Cancer Res. (2006) pmid: 17189383
88. Skardelly M, et al. Transl Oncol (2009) pmid: 19701495
89. Int. J. Biochem. Cell Biol. (1999) pmid: 10582339
90. Semin. Oncol. (2004) pmid: 15175998
91. Gao J, et al. Sci Signal (2013) pmid: 23550210
92. Zack TI, et al. Nat. Genet. (2013) pmid: 24071852
93. Beroukhim R, et al. Nature (2010) pmid: 20164920
94. Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436
95. Baccarani M, et al. Haematologica (2007) pmid: 17666373
96. Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859
97. Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984
98. Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384
99. Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450
100. Debiec-Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069
101. Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908
102. Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008
103. Florian S, et al. Leuk. Res. (2006) pmid: 16406018
104. Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816
105. Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148
106. Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423
107. Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352
108. Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127
109. Hus M, et al. Leuk. Res. (2011) pmid: 21093052
110. Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172
111. Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261
112. Jain N, et al. Leuk. Res. (2009) pmid: 19013640
113. Jovanovic JV, et al. Blood (2007) pmid: 17299092
114. Kang HJ, et al. Acta Oncol (2012) pmid: 22150077
115. Klion AD, et al. Blood (2004) pmid: 14504092
116. Kobayashi M, et al. Respirology (2009) pmid: 19192229
117. Kocáková I, et al. Klin Onkol (2014) pmid: 24635438
118. Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453
119. Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636
120. Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029
121. Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885
122. Pardanani A, et al. Blood (2003) pmid: 12842979
123. Pardanani A, et al. Blood (2004) pmid: 15284118
124. Qu SQ, et al. Oncotarget (2016) pmid: 27120808
125. Score J, et al. Leukemia (2006) pmid: 16498388
126. Shah S, et al. J Hematol Oncol (2014) pmid: 24669761
127. Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757
128. Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486
129. von Bubnoff N, et al. Leukemia (2005) pmid: 15618966
130. Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659
131. Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666
132. Al-Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309
133. Lierman E, et al. Blood (2006) pmid: 16645167
134. Lierman E, et al. Leukemia (2009) pmid: 19212337
135. Metzgeroth G, et al. Leukemia (2012) pmid: 21818111
136. Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526
137. von Bubnoff N, et al. Oncogene (2011) pmid: 20972453
138. Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647
139. Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858
140. Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084
141. Weisberg E, et al. Gastroenterology (2006) pmid: 17087936
142. Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737
143. Grellety T, et al. Future Sci OA (2015) pmid: 28031906
144. Kollàr A, et al. Clin Sarcoma Res (2014) pmid: 25905001
145. Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035
146. Motomura K, et al. J. Neuropathol. Exp. Neurol. (2013) pmid: 23242283
147. Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337
148. Alentorn A, et al. Neuro-oncology (2012) pmid: 23074200
149. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
150. Nature (2008) pmid: 18772890
151. Hoadley KA, et al. Cell (2018) pmid: 29625048

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

152. Ellrott K, et al. Cell Syst (2018) pmid: 29596782
153. Taylor AM, et al. Cancer Cell (2018) pmid: 29622463
154. Gao Q, et al. Cell Rep (2018) pmid: 29617662
155. Liu J, et al. Cell (2018) pmid: 29625055
156. Sanchez-Vega F, et al. Cell (2018) pmid: 29625050
157. Song K, et al. Am J Cancer Res (2018) pmid: 29888103
158. Szerlip NJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22323597
159. Andrae J, et al. Genes Dev. (2008) pmid: 18483217
160. Flavahan WA, et al. Nature (2016) pmid: 26700815
161. Roszik J, et al. Sci Rep (2016) pmid: 26787600
162. Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251
163. Koschmann C, et al. Oncotarget (2016) pmid: 27582545
164. Puget S, et al. PLoS ONE (2012) pmid: 22389665
165. Corless CL, et al. J. Clin. Oncol. (2005) pmid: 15928335
166. Elling C, et al. Blood (2011) pmid: 21224473
167. Dai J, et al. Clin. Cancer Res. (2013) pmid: 24132921
168. Lasota J, et al. Lab. Invest. (2004) pmid: 15146165
169. Velghe AI, et al. Oncogene (2014) pmid: 23752188
170. Paugh BS, et al. Cancer Res. (2013) pmid: 23970477
171. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
172. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
173. Turner NC, et al. N. Engl. J. Med. (2015) pmid: 26030518
174. Patnaik A, et al. Cancer Discov (2016) pmid: 27217383
175. Peguero et al., 2016; ASCO Abstract 2528
176. Konecny et al., 2016; ASCO Abstract 5557
177. Bax DA, et al. Clin. Cancer Res. (2010) pmid: 20570930
178. Hodgson JG, et al. Neuro-oncology (2009) pmid: 19139420
179. Ruano Y, et al. Mol. Cancer (2006) pmid: 17002787
180. Costello JF, et al. Cancer Res. (1997) pmid: 9102208
181. Li B, et al. Oncol. Rep. (2012) pmid: 22736304
182. Lam PY, et al. Br J Neurosurg (2000) pmid: 10884881
183. Chen SM, et al. World J Surg Oncol (2013) pmid: 23594394
184. Michaud K, et al. Cancer Res. (2010) pmid: 20354191
185. Meyerson M, et al. Mol. Cell. Biol. (1994) pmid: 8114739
186. Grossel MJ, et al. J. Cell. Biochem. (2006) pmid: 16294322
187. Choi YJ, et al. Oncogene (2014) pmid: 23644662
188. Cell (1995) pmid: 7736585
189. Musgrove EA, et al. Nat. Rev. Cancer (2011) pmid: 21734724
190. Ismail A, et al. Clin. Cancer Res. (2011) pmid: 21593195
191. van Dekken H, et al. Cancer Genet. Cytogenet. (2009) pmid: 19167610
192. Kalev P, et al. Cancer Cell (2021) pmid: 33450196
193. Marjon K, et al. Cell Rep (2016) pmid: 27068473
194. Mavrakis KJ, et al. Science (2016) pmid: 26912361
195. Kryukov GV, et al. Science (2016) pmid: 26912360
196. Heist et al., 2019; AACR-NCI-EORTC Abstract B116
197. Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521
198. Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072
199. Srour N, et al. Cancer Cell (2019) pmid: 31287990
200. Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320
201. Smith CR, et al. J Med Chem (2022) pmid: 35041419
202. Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154
203. Tang B, et al. Cancer Res. (2018) pmid: 29844120
204. Munshi PN, et al. Oncologist (2014) pmid: 24928612
205. de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376
206. Lubin M, et al. PLoS ONE (2009) pmid: 19478948
207. Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330
208. Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602
209. Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207
210. Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358
211. Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432
212. Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241
213. Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081
214. Alhalabi O, et al. Nat Commun (2022) pmid: 35379845
215. Wei R, et al. Sci Rep (2016) pmid: 27929028
216. Zhao M, et al. BMC Genomics (2016) pmid: 27556634
217. Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366
218. Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491
219. Marcé S, et al. Clin. Cancer Res. (2006) pmid: 16778103
220. Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769
221. Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867
222. Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930
223. Li CF, et al. Oncotarget (2014) pmid: 25426549
224. He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376
225. Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958
226. Mirebeau D, et al. Haematologica (2006) pmid: 16818274
227. Becker AP, et al. Pathobiology (2015) pmid: 26088413
228. Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286
229. Bistulfi G, et al. Oncotarget (2016) pmid: 26910893
230. Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435
231. Maccioni L, et al. BMC Cancer (2013) pmid: 23816148
232. Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288
233. Lin X, et al. Cancer Sci. (2017) pmid: 27960044
234. Zhi L, et al. J Cancer (2016) pmid: 27994653
235. Gu F, et al. Br. J. Cancer (2013) pmid: 23361049
236. Limm K, et al. PLoS ONE (2016) pmid: 27479139
237. Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827
238. Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702
239. Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084
240. Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184
241. Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491
242. Goga A, et al. Nat. Med. (2007) pmid: 17589519
243. Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400
244. Dammert MA, et al. Nat Commun (2019) pmid: 31375684
245. Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889
246. Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717
247. Wang L, et al. Mol Oncol (2017) pmid: 28417568
248. Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068
249. Li Y, et al. Thyroid (2018) pmid: 30226440
250. Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165
251. Park SI, et al. Target Oncol (2019) pmid: 31429028
252. Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133
253. Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631
254. Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922
255. He J, et al. Anticancer Drugs (2019) pmid: 30540594
256. Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345
257. Effenberger M, et al. Oncotarget (2017) pmid: 29156762
258. Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944
259. Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584
260. Delmore JE, et al. Cell (2011) pmid: 21889194
261. Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863
262. Lovén J, et al. Cell (2013) pmid: 23582323
263. Otto C, et al. Neoplasia (2019) pmid: 31734632
264. Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964
265. Pei Y, et al. Cancer Cell (2016) pmid: 26977882
266. Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636
267. Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296
268. Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784
269. Pereira CB, et al. PLoS ONE (2013) pmid: 23555992
270. Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827
271. Arango D, et al. Cancer Res. (2001) pmid: 11406570
272. Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787
273. Felicella MM, et al. Clin. Neuropathol. () pmid: 22720694
274. Faria et al. 2008; 18369647
275. Hu YH, et al. Chin. Med. J. (2012) pmid: 22884072
276. De Salvo M, et al. Int. J. Radiat. Biol. (2011) pmid: 21405945
277. Cenci T, et al. Am. J. Clin. Pathol. (2012) pmid: 22912356
278. Lassman AB, et al. Neuron Glia Biol. (2004) pmid: 17047730
279. Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903
280. Nesbit CE, et al. Oncogene (1999) pmid: 10378696
281. Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194
282. Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779
283. Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829
284. Elvin JA, et al. Oncologist (2017) pmid: 28283584
285. Gao J, et al. Curr Oncol (2015) pmid: 26715889
286. Gopalan et al., 2014; ASCO Abstract 8077
287. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
288. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
289. Johnson DB, et al. Oncologist (2014) pmid: 24797823
290. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
291. Gamble LD, et al. Oncogene (2012) pmid: 21725357
292. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
293. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
294. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
295. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
296. Shapiro et al., 2013; ASCO Abstract 2500
297. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
298. Ceccarelli M, et al. Cell (2016) pmid: 26824661
299. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
300. Weber RG, et al. Oncogene (2007) pmid: 16909113
301. Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817
302. Feng J, et al. Cancer (2012) pmid: 21713760
303. Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552
304. Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312
305. Quelle DE, et al. Cell (1995) pmid: 8521522
306. Mutat. Res. (2005) pmid: 15878778
307. Gazzeri S, et al. Oncogene (1998) pmid: 9484839

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

308. Oncogene (1999) pmid: 10498883
309. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
310. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
311. Ruas M, et al. Oncogene (1999) pmid: 10498896
312. Jones R, et al. Cancer Res. (2007) pmid: 17909018
313. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
314. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
315. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
316. Gombart AF, et al. Leukemia (1997) pmid: 9324288
317. Yang R, et al. Cancer Res. (1995) pmid: 7780957
318. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
319. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
320. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
321. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
322. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
323. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
324. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
325. Koh J, et al. Nature (1995) pmid: 7777061
326. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
327. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
328. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
329. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
330. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
331. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
332. Rutter JL, et al. Oncogene (2003) pmid: 12853981
333. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
334. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
335. Zhang Y, et al. Cell (1998) pmid: 9529249
336. Jafri M, et al. Cancer Discov (2015) pmid: 25873077
337. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
338. Adv Exp Med Biol (2010) pmid: 20687502
339. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
340. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
341. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
342. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
343. Kaufman DK, et al. Neurology (1993) pmid: 8414022
344. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
345. Chan AK, et al. Clin Neuropathol () pmid: 28699883
346. Beuselinck B, et al. Acta Oncol (2018) pmid: 29095068
347. Song Y, et al. Chin. Med. J. (2015) pmid: 26228213
348. Dornbusch J, et al. PLoS ONE (2013) pmid: 24086736
349. Terakawa T, et al. Urol. Oncol. (2013) pmid: 21478036
350. You D, et al. World J Urol (2015) pmid: 24710685
351. Silva E, et al. Breast J () pmid: 25639617
352. Baumgarten P, et al. Neuro-oncology (2016) pmid: 26627848
353. Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667
354. Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283
355. Duda DG, et al. Oncologist (2010) pmid: 20484123
356. Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973
357. Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443
358. Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624
359. Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754
360. Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552
361. Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311
362. Sánchez-Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155
363. Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548
364. Mok T, et al. J Thorac Oncol (2014) pmid: 24807156
365. An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128
366. Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426
367. Cohen EE, et al. Lancet Oncol. (2009) pmid: 19201650
368. Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005
369. Lee EQ, et al. Clin. Cancer Res. (2018) pmid: 29941486
370. Xu L, et al. Cancer Res. (2009) pmid: 19826039
371. Heist RS, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25605928
372. Carroll RS, et al. Cancer (1999) pmid: 10506722
373. Plate KH, et al. Int. J. Cancer (1994) pmid: 7525492
374. Kuczynski EA, et al. Oncology (2011) pmid: 21985798
375. Biol. Pharm. Bull. (2011) pmid: 22130231
376. Debiec-Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552
377. Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351
378. Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049
379. Metzgeroth G, et al. Leukemia (2007) pmid: 17377585
380. Hassler MR, et al. Springerplus (2014) pmid: 25674429
381. Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313
382. Reardon DA, et al. Cancer (2012) pmid: 22371319
383. Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690
384. Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753
385. Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987
386. Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383
387. Sako H, et al. PLoS ONE (2014) pmid: 25221952
388. Hughes TP, et al. Blood (2014) pmid: 24335106
389. Takahashi N, et al. Biomark Res (2014) pmid: 24650752
390. Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255
391. Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758
392. Villar VH, et al. PLoS ONE (2012) pmid: 22662203
393. Quintás-Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790
394. Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405
395. Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153
396. Dişel U, et al. Lung Cancer (2011) pmid: 20970876
397. Park SH, et al. Invest New Drugs (2012) pmid: 22270258
398. Catania C, et al. Onco Targets Ther (2014) pmid: 24855380
399. Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867
400. Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300
401. Fumagalli et al., 2012; ESMO Abstract 1491P
402. Zustovich et al., 2013; 23898124; Reardon et al.
403. Lee EQ, et al. Neuro-oncology (2012) pmid: 23099651
404. Peereboom DM, et al. Neuro-oncology (2013) pmid: 23328813
405. Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603
406. Karajannis MA, et al. Neuro-oncology (2014) pmid: 24803676
407. Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458
408. Buchbinder EI, et al. Cancer (2015) pmid: 26264378
409. Reichardt P, et al. BMC Cancer (2016) pmid: 26772734
410. Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655
411. Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347
412. Pan E, et al. J. Neurooncol. (2012) pmid: 22832897
413. Kreisl TN, et al. J. Neurooncol. (2013) pmid: 23086433
414. Balaña C, et al. Target Oncol (2014) pmid: 24424564
415. Hutterer M, et al. Neuro-oncology (2014) pmid: 24311637

Electronically signed by Erik Williams, M.D. | 28 July 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531